B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: A real-world case series study.

[1]  Xin Eric Wang,et al.  Efficacy and safety of modified reduced-dose rituximab in Chinese patients with neuromyelitis optica spectrum disorder: A retrospective cohort study , 2021, Journal of the Neurological Sciences.

[2]  V. Shaygannejad,et al.  Efficacy and safety of rituximab in treating patients with Neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis. , 2020, Autoimmunity reviews.

[3]  Ling Li,et al.  Retrospective Observation of Low-Dose Rituximab Treatment in Chinese Patients With Neuromyelitis Optica Spectrum Disorders in a Real-World Setting , 2020, Frontiers in Neurology.

[4]  S. Vukusic,et al.  Evaluation of efficacy and tolerability of first-line therapies in NMOSD , 2020, Neurology.

[5]  Haiqiang Jin,et al.  A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders. , 2020, Multiple sclerosis and related disorders.

[6]  M. Sormani,et al.  Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. , 2019, Multiple sclerosis and related disorders.

[7]  Jae-Won Hyun,et al.  Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder , 2019, Neurochemistry International.

[8]  K. Fujihara.  Neuromyelitis optica spectrum disorders: still evolving and broadening , 2019, Current opinion in neurology.

[9]  R. Gold,et al.  Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders , 2018, Journal of Neurology.

[10]  Yeseul Kim,et al.  Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[11]  M. Ticchioni,et al.  Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders , 2018, Neurology and Therapy.

[12]  F. Zipp,et al.  Monitoring B-cell repopulation after depletion therapy in neurologic patients , 2018, Neurology: Neuroimmunology & Neuroinflammation.

[13]  Jia Li,et al.  Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder , 2018, Journal of Neuroimmunology.

[14]  S. Vukusic,et al.  Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders , 2018, Revue neurologique.

[15]  P. Cabre,et al.  Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study , 2018, Journal of Neurology.

[16]  Chun-juan Wang,et al.  Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder , 2018, Journal of the Neurological Sciences.

[17]  P. Bai,et al.  Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study , 2017, Acta Neurologica Belgica.

[18]  M. Ticchioni,et al.  Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study , 2017, Journal of the Neurological Sciences.

[19]  V. Damato,et al.  Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis. , 2016, JAMA neurology.

[20]  D. Centonze,et al.  Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study , 2016, Journal of Neurology.

[21]  G. Comi,et al.  Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients , 2016, Multiple sclerosis.

[22]  J. de Seze,et al.  An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica , 2016, Therapeutic advances in neurological disorders.

[23]  J. Joo,et al.  Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints , 2016, Multiple sclerosis.

[24]  D. Furst,et al.  Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years , 2015, The Journal of Rheumatology.

[25]  J. Joo,et al.  Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab. , 2015, JAMA neurology.

[26]  A. Traboulsee,et al.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.

[27]  Terry J. Smith,et al.  B lymphocytes in neuromyelitis optica , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[28]  S. Galetta,et al.  Analysis of the treatment of neuromyelitis optica , 2015, Journal of the Neurological Sciences.

[29]  B. Kieseier,et al.  Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder , 2015, Journal of Neurology.

[30]  Jacqueline A Palace,et al.  Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. , 2014, JAMA neurology.

[31]  Su-Hyun Kim,et al.  A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. , 2013, JAMA neurology.

[32]  Chunshui Yu,et al.  Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica , 2013, Neurology.

[33]  P. Pillans,et al.  Experience with low‐dose rituximab in off‐label indications at two tertiary hospitals , 2013, Internal medicine journal.

[34]  V. Kuchroo,et al.  Immunology of neuromyelitis optica: a T cell–B cell collaboration , 2013, Annals of the New York Academy of Sciences.

[35]  J. Wolinsky,et al.  Variable results after rituximab in neuromyelitis optica , 2012, Journal of the Neurological Sciences.

[36]  E. Frohman,et al.  Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success , 2012, Multiple sclerosis.

[37]  Su-Hyun Kim,et al.  Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. , 2011, Archives of neurology.

[38]  K. Chan,et al.  Brain involvement in neuromyelitis optica spectrum disorders. , 2011, Archives of neurology.

[39]  M. Krumbholz,et al.  Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab , 2011, Neurology.

[40]  Dennis McGonagle,et al.  Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[41]  Aaron E Miller,et al.  Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. , 2008, Archives of neurology.

[42]  E. Waubant,et al.  An open label study of the effects of rituximab in neuromyelitis optica , 2005, Neurology.

[43]  Ichiro Nakashima,et al.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis , 2004, The Lancet.